Can advanced kidney cancer be cured? How long can you live with advanced kidney cancer

The above methods have their own advantages in the middle and advanced stages of kidney cancer, but there are also certain drawbacks. Kidney cancer is not highly sensitive to radiotherapy, but for patients with advanced kidney cancer, radiotherapy can reduce local pain, hematuria and alleviate toxic symptoms to a certain extent, but because radiotherapy can also harm normal cells, radiotherapy should be used with caution for patients with advanced kidney cancer with weak physical function. Kidney cancer is also not sensitive to chemotherapy, and cyclophosphamide, 6-mercaptopurine, vinblastine, dactinomycin and cyclohexylnitrosis are slightly valuable, and if they can be combined with radiotherapy, the effect is better than chemotherapy or radiotherapy alone.

In addition, immunity** can expand the effect of cellular and antibody immune responses through immunoactive cells, enhance the host's anti-tumor ability, and the efficacy has been more and more widely recognized. For example, interferon can enhance the activity of natural killer cells, and is currently the most effective drug for advanced kidney cancer. The above three methods are harmful to the human body, and traditional Chinese medicine can be combined in the middle and advanced stage of kidney cancer to play a role in increasing efficiency and reducing toxicity.

For patients with advanced kidney cancer who have a wide range of metastasis, weak physical function, and have difficulty tolerating chemotherapy, traditional Chinese medicine can be used for conservative **, although the short-term effect is not as obvious as chemotherapy, but the long-term effect is good, and it has an obvious effect in improving the quality of life and prolonging survival.

Once the kidney cancer has progressed to an advanced stage, it is very difficult to completely **, and the current ** for advanced kidney cancer is mainly to reduce symptoms and prolong survival. Methods include chemoradiotherapy, biology and other methods.

If a patient with kidney cancer reaches an advanced stage, then he will have less time to survive. The survival time of patients with kidney cancer is directly related to the clinical stage: the five-year survival rate of stage 1 kidney cancer can reach 95% for patients who can be surgically resected; The five-year survival rate for stage II kidney cancer is about 80%; The five-year survival rate of stage III kidney cancer is about 50%; The five-year survival rate for stage IV kidney cancer is less than 20%.

The influencing factors of survival in advanced kidney cancer are very complex, and are related to many factors such as clinical stage, means, and effects. The survival time of patients with advanced kidney cancer is relatively short, while early detection and early ** can prolong the survival time of patients.

How long can you live depends on the health and recuperation, and can you live longer with the right care?

The question of how long you can live in an advanced stage of kidney cancer cannot give you an answer. There are many factors that affect the survival of patients with advanced kidney cancer, such as the physical condition of the disease, the choice of mode, the post-care care, and the complexity of the disease, all of which are important factors affecting the survival period.

The ** method of advanced kidney cancer is mainly comprehensive**. Because chemoradiotherapy is not very sensitive to kidney cancer, and it is very toxic, it is easy to seriously damage the patient's organs, decline the immune mechanism, and aggravate the condition, so traditional Chinese medicine is generally used to carry out the comprehensive treatment of the whole body, so as to alleviate the pain of the patient and prolong the life cycle for the purpose.

Locally advanced, there are 5 years of less, how long can you live, depending on the tumor and its factors, the disease should be clarified first, and it can be treated as soon as possible.

Historically, the average survival time for patients with metastatic renal cell carcinoma was 12-14 months. However, the new targeted drug (the first-line drug approved in China is Sutent) can extend this time to about 2 years. It should be noted that:

2 years is the average time for a large sample size of patients, and this survival time can vary greatly from a few months to several years, with more than 10 years of survival still healthy.

In recent years, the emergence of targeted drugs is a step forward in advanced kidney cancer. Sutent represents the advent of a new round of targeted **, which can directly attack tumors without the toxic side effects of conventional chemotherapy, and its clinical advantages are obvious.